Predictors of duloxetine adherence and persistence in patients with fibromyalgia

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 193-201

  Cui, Zhanglin ^a   Zhao, Yang ^a   Novick, Diego ^a   Faries, Douglas ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Duloxetine; Fibromyalgia Introduction; Medication adherence; Medication persistence; Subgroup analysis

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; DYSLIPIDEMIA; FEMALE; FIBROMYALGIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

EID: 84871595356     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S31800     Document Type: Article

References (27)

1. Wright CL, Mist SD, Ross RL, Jones KD. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol. 2010;6(5):745-756.
2. Schmidt-Wilcke T, Clauw DJ. Pharmacotherapy in fibromyalgia (FM)-implications for the underlying pathophysiology. Pharmacol Ther. 2010;127(3):283-294.
3. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-1508.
4. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7(5):362-368.
5. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care. 2009;15(Suppl 7):S197-S218.
6. Annemans L, Le Lay K, Taieb C. Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics. 2009;27(7): 547-559.
7. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91(1-2):165-175.
8. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7: 309-338.
9. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009;6(4):703-712.
10. Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med. 2010;35(3): 294-303.
11. Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001;40(3):290-296.
12. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35(5):550-556.
13. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
14. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984.
15. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.
16. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2009;1:91-102.
17. Kleinman NL, Sanchez RJ, Lynch WD, Cappelleri JC, Beren IA, Joshi AV. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs standard of care. Pain Pract. 2011;11(6): 540-551.
18. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11(3):204-216.
19. Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine. Pain Pract. 2011;11(4):381-391.
20. Wu N, Chen S, Boulanger L, Rao P, Zhao Y. Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine. Curr Med Res Opin. 2011;27(6):1131-1139.
21. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1): 44-47.
22. American Psychiatric Association. Practice Guideline for Treatment of Patients with Major Depressive Disorder, 2nd ed. Washington: American Psychiatric Association Press; 2000.
23. Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med. 2011;124(10):955-960.
24. Serra E. Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? Nat Clin Pract Neurol. 2008;4:594-595.
25. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21.
26. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol. 1989;16(4):527-532.
27. Solitar BM. Fibromyalgia: knowns, unknowns, and current treatment. Bull NYU Hosp Jt Dis. 2010;68(3):157-161.